XGN
Exagen Inc.
Price Chart
Latest Quote
$3.83
Current Price| Previous Close | $3.68 |
| Open | $3.64 |
| Day High | $4.01 |
| Day Low | $3.59 |
| Volume | 713,383 |
Stock Information
| Shares Outstanding | 22.66M |
| Total Debt | $28.17M |
| Cash Equivalents | $35.65M |
| Revenue | $63.60M |
| Net Income | $-19.04M |
| Sector | Healthcare |
| Industry | Diagnostics & Research |
| Market Cap | $86.80M |
| EPS (TTM) | $-0.93 |
| Exchange | NGM |
📊 Custom Metrics & Score
Score: 7/42| Debt to Equity | 2.41 |
| Debt to Earnings | 0.69 |
| Current Ratio | 2.70 |
| Quick Ratio | 2.21 |
| Avg Revenue Growth | 3.80% |
| Profit Margin | -27.17% |
| Return on Equity | -158.44% |
| Avg FCF Growth | -9.77% |
| FCF Yield | -15.89% |
Score Explanation: The perfect score is 42/42 based on debt levels, profitability, growth rates, and cash flow metrics. FCF Yield is weighted most heavily as it shows what return the business currently generates.
Recent Price History
| Date | Close | Volume |
|---|---|---|
| 2026-02-02 | $3.83 | 713,383 |
| 2026-01-30 | $3.68 | 1,357,900 |
| 2026-01-29 | $3.95 | 389,200 |
| 2026-01-28 | $4.06 | 357,200 |
| 2026-01-27 | $4.31 | 488,200 |
| 2026-01-26 | $4.41 | 736,000 |
| 2026-01-23 | $4.60 | 459,800 |
| 2026-01-22 | $4.89 | 792,500 |
| 2026-01-21 | $4.73 | 771,800 |
| 2026-01-20 | $4.74 | 828,400 |
| 2026-01-16 | $4.69 | 563,400 |
| 2026-01-15 | $4.83 | 504,400 |
| 2026-01-14 | $5.09 | 2,455,100 |
| 2026-01-13 | $5.15 | 980,600 |
| 2026-01-12 | $5.95 | 922,900 |
| 2026-01-09 | $6.34 | 438,400 |
| 2026-01-08 | $6.17 | 221,400 |
| 2026-01-07 | $6.02 | 300,800 |
| 2026-01-06 | $6.09 | 493,400 |
| 2026-01-05 | $5.95 | 316,800 |
About Exagen Inc.
Exagen Inc. designs, develops, and commercializes various testing products under the AVISE brand in the United States. The company enables healthcare providers to care for patients through the diagnosis, prognosis, and monitoring of complex rheumatic, and autoimmune and autoimmune-related diseases, including systemic lupus erythematosus (SLE) and rheumatoid arthritis (RA). Its lead testing product is AVISE CTD that enables differential diagnosis for patients presenting with symptoms indicative of various connective tissue diseases (CTDs) and other related diseases with overlapping symptoms. The company offers AVISE Lupus platform, a cornerstone of the SLE assessment that begins by quantifying the level of CB-CAPs biomarkers (EC4d and BC4d) in the patient's blood; and AVISE APS that aids in the diagnosis and management of APS. In addition, it provides AVISE Vasculitis AAV, which utilizes a testing panel of individual analytes to provide physicians with results in the assessment and monitoring of anti-neutrophil cytoplasmic antibody associated vasculitis; AVISE Anti-Histone, a test for autoantibodies to histone proteins; AVISE SLE Prognostic, a panel of autoantibodies for assessing the potential for complications affecting the kidney, brain, and cardiovascular system; and AVISE Anti-CarP, a biomarker-driven RA prognostic test. Further, the company offers AVISE SLE Monitor, a blood test that employs CB-CAPs technology; AVISE MTX, a patented and validated blood test; and AVISE HCQ, a blood test to monitor levels of hydroxychloroquine. It has a research collaboration and license agreement with Allegheny Health Network (AHN) Research Institute to develop T-Cell biomarkers. The company was formerly known as Exagen Diagnostics, Inc. and changed its name to Exagen Inc. in January 2019. Exagen Inc. was incorporated in 2002 and is headquartered in Vista, California.
📰 Latest News
How The Exagen (XGN) Story Is Shifting With A New Analyst Price Target
Simply Wall St. • 2026-01-27T22:08:13Z
How Recent Analyst Resets Are Reframing The Exagen (XGN) Investment Story
Simply Wall St. • 2026-01-12T18:08:08Z
How the Narrative Surrounding Exagen Is Evolving After New Guidance and Price Target Upgrades
Simply Wall St. • 2025-12-22T07:06:18Z
What New Catalysts Are Shaping the Narrative for Exagen?
Simply Wall St. • 2025-12-08T00:10:12Z
Why Analysts Are Updating Exagen’s Story After Higher Targets and Growth Outlook
Simply Wall St. • 2025-11-23T20:06:54Z
How Analyst Views Are Shifting the Story for Exagen Amid New Growth Signals
Simply Wall St. • 2025-11-07T07:13:28Z
Exagen (XGN): Revenue Growth Outlook Challenges Bearish Sentiment as Valuation Remains Undemanding
Simply Wall St. • 2025-11-05T00:25:59Z
Exagen Inc (XGN) Q3 2025 Earnings Call Highlights: Record Revenue and Strategic Expansion ...
GuruFocus.com • 2025-11-04T21:08:03Z
Exagen Inc. (XGN) Reports Q3 Loss, Tops Revenue Estimates
Zacks • 2025-11-04T14:10:03Z
How the Narrative Around Exagen Is Shifting With Analyst Upgrades and Growth Signals
Simply Wall St. • 2025-10-23T05:07:03Z
Income Statement (Annual)
Revenue
| Metric | 2024-12-31 | 2023-12-31 | 2022-12-31 | 2021-12-31 |
|---|---|---|---|---|
| Reconciled Cost Of Revenue | $22,529,000 | $23,092,000 | $24,214,000 | $20,588,000 |
| Cost Of Revenue | $22,529,000 | $23,092,000 | $24,214,000 | $20,588,000 |
| Total Revenue | $55,641,000 | $52,548,000 | $45,563,000 | $48,299,000 |
| Operating Revenue | $55,641,000 | $52,548,000 | $45,563,000 | $48,299,000 |
Expenses
| Metric | 2024-12-31 | 2023-12-31 | 2022-12-31 | 2021-12-31 |
|---|---|---|---|---|
| Interest Expense | $2,234,000 | $2,335,000 | $2,448,000 | $2,625,000 |
| Total Expenses | $69,277,000 | $75,385,000 | $86,108,000 | $72,366,000 |
| Net Non Operating Interest Income Expense | $-1,467,000 | $-819,000 | $-1,618,000 | $-2,609,000 |
| Interest Expense Non Operating | $2,234,000 | $2,335,000 | $2,448,000 | $2,625,000 |
| Operating Expense | $46,748,000 | $52,293,000 | $61,894,000 | $51,778,000 |
| Other Income Expense | - | - | $-5,506,000 | $16,000 |
| Other Non Operating Income Expenses | - | - | - | $16,000 |
Income & Earnings
| Metric | 2024-12-31 | 2023-12-31 | 2022-12-31 | 2021-12-31 |
|---|---|---|---|---|
| Net Income From Continuing Operation Net Minority Interest | $-15,115,000 | $-23,689,000 | $-47,387,000 | $-26,851,000 |
| Net Interest Income | $-1,467,000 | $-819,000 | $-1,618,000 | $-2,609,000 |
| Interest Income | $767,000 | $1,516,000 | $830,000 | $16,000 |
| Normalized Income | $-15,115,000 | $-23,689,000 | $-41,914,036 | $-26,851,000 |
| Net Income From Continuing And Discontinued Operation | $-15,115,000 | $-23,689,000 | $-47,387,000 | $-26,851,000 |
| Total Operating Income As Reported | $-13,636,000 | $-22,837,000 | $-46,051,000 | $-24,067,000 |
| Net Income Common Stockholders | $-15,115,000 | $-23,689,000 | $-47,387,000 | $-26,851,000 |
| Net Income | $-15,115,000 | $-23,689,000 | $-47,387,000 | $-26,851,000 |
| Net Income Including Noncontrolling Interests | $-15,115,000 | $-23,689,000 | $-47,387,000 | $-26,851,000 |
| Net Income Continuous Operations | $-15,115,000 | $-23,689,000 | $-47,387,000 | $-26,851,000 |
| Pretax Income | $-15,103,000 | $-23,656,000 | $-47,669,000 | $-26,676,000 |
| Interest Income Non Operating | $767,000 | $1,516,000 | $830,000 | $16,000 |
| Operating Income | $-13,636,000 | $-22,837,000 | $-40,545,000 | $-24,067,000 |
| Gross Profit | $33,112,000 | $29,456,000 | $21,349,000 | $27,711,000 |
| Special Income Charges | - | $0 | $-5,506,000 | $0 |
Per Share Metrics
| Metric | 2024-12-31 | 2023-12-31 | 2022-12-31 | 2021-12-31 |
|---|---|---|---|---|
| Diluted EPS | $-0.83 | $-1.34 | $-2.77 | $-1.68 |
| Basic EPS | $-0.83 | $-1.34 | $-2.77 | $-1.68 |
Other
| Metric | 2024-12-31 | 2023-12-31 | 2022-12-31 | 2021-12-31 |
|---|---|---|---|---|
| Tax Effect Of Unusual Items | $0 | $0 | $-33,036 | $0 |
| Tax Rate For Calcs | $0 | $0 | $0 | $0 |
| Normalized EBITDA (Bullshit earnings) | $-11,145,000 | $-19,153,000 | $-38,158,000 | $-23,103,000 |
| Reconciled Depreciation | $1,724,000 | $2,168,000 | $1,557,000 | $948,000 |
| EBITDA (Bullshit earnings) | $-11,145,000 | $-19,153,000 | $-43,664,000 | $-23,103,000 |
| EBIT | $-12,869,000 | $-21,321,000 | $-45,221,000 | $-24,051,000 |
| Diluted Average Shares | $18,203,044 | $17,679,467 | $17,082,348 | $15,972,256 |
| Basic Average Shares | $18,203,044 | $17,679,467 | $17,082,348 | $15,972,256 |
| Diluted NI Availto Com Stockholders | $-15,115,000 | $-23,689,000 | $-47,387,000 | $-26,851,000 |
| Tax Provision | $12,000 | $33,000 | $-282,000 | $175,000 |
| Research And Development | $5,375,000 | $4,865,000 | $9,876,000 | $7,237,000 |
| Selling General And Administration | $41,373,000 | $47,428,000 | $52,018,000 | $44,541,000 |
| Total Unusual Items | - | $0 | $-5,506,000 | $0 |
| Total Unusual Items Excluding Goodwill | - | $0 | $-5,506,000 | $0 |
| Impairment Of Capital Assets | - | $0 | $5,506,000 | $0 |
Balance Sheet (Annual)
Assets
| Metric | 2024-12-31 | 2023-12-31 | 2022-12-31 | 2021-12-31 |
|---|---|---|---|---|
| Net Tangible Assets | $9,540,000 | $22,694,000 | $42,460,000 | $79,430,000 |
| Total Assets | $44,689,000 | $56,944,000 | $86,221,000 | $123,445,000 |
| Total Non Current Assets | $8,234,000 | $9,103,000 | $13,610,000 | $10,711,000 |
| Other Non Current Assets | $550,000 | $616,000 | $528,000 | $433,000 |
| Current Assets | $36,455,000 | $47,841,000 | $72,611,000 | $112,734,000 |
| Other Current Assets | $859,000 | $1,926,000 | $236,000 | $490,000 |
| Prepaid Assets | $5,725,000 | $2,871,000 | $3,907,000 | $3,148,000 |
| Receivables | $7,835,000 | $6,551,000 | $6,077,000 | $9,654,000 |
| Accounts Receivable | $7,835,000 | $6,551,000 | $6,077,000 | $9,654,000 |
| Allowance For Doubtful Accounts Receivable | $-7,800 | $-6,600 | - | - |
| Gross Accounts Receivable | $7,842,800 | $6,557,600 | - | - |
| Cash Cash Equivalents And Short Term Investments | $22,036,000 | $36,493,000 | $62,391,000 | $99,442,000 |
| Cash And Cash Equivalents | $22,036,000 | $36,493,000 | $62,391,000 | $99,442,000 |
| Goodwill And Other Intangible Assets | - | - | $0 | $5,506,000 |
Debt
| Metric | 2024-12-31 | 2023-12-31 | 2022-12-31 | 2021-12-31 |
|---|---|---|---|---|
| Total Debt | $23,005,000 | $23,231,000 | $35,201,000 | $28,065,000 |
| Long Term Debt And Capital Lease Obligation | $21,486,000 | $21,991,000 | $33,271,000 | $27,478,000 |
| Long Term Debt | $19,822,000 | $19,231,000 | $28,778,000 | $27,478,000 |
| Current Debt And Capital Lease Obligation | $1,519,000 | $1,240,000 | $1,930,000 | $587,000 |
| Current Debt | $423,000 | $264,000 | $190,000 | - |
| Other Current Borrowings | $423,000 | $264,000 | $190,000 | - |
Liabilities
| Metric | 2024-12-31 | 2023-12-31 | 2022-12-31 | 2021-12-31 |
|---|---|---|---|---|
| Total Liabilities Net Minority Interest | $35,149,000 | $34,250,000 | $43,761,000 | $38,509,000 |
| Total Non Current Liabilities Net Minority Interest | $21,643,000 | $22,348,000 | $34,138,000 | $29,191,000 |
| Other Non Current Liabilities | $157,000 | $357,000 | $867,000 | $1,407,000 |
| Current Liabilities | $13,506,000 | $11,902,000 | $9,623,000 | $9,318,000 |
| Payables And Accrued Expenses | $11,987,000 | $10,662,000 | $7,248,000 | $8,731,000 |
| Payables | $4,137,000 | $3,131,000 | $3,046,000 | $2,492,000 |
| Accounts Payable | $4,137,000 | $3,131,000 | $3,046,000 | $2,492,000 |
| Other Current Liabilities | - | $302,000 | $445,000 | - |
| Interest Payable | - | $139,000 | $142,000 | $139,000 |
| Non Current Deferred Liabilities | - | - | $0 | $306,000 |
| Non Current Deferred Taxes Liabilities | - | - | $0 | $306,000 |
Equity
| Metric | 2024-12-31 | 2023-12-31 | 2022-12-31 | 2021-12-31 |
|---|---|---|---|---|
| Common Stock Equity | $9,540,000 | $22,694,000 | $42,460,000 | $84,936,000 |
| Total Equity Gross Minority Interest | $9,540,000 | $22,694,000 | $42,460,000 | $84,936,000 |
| Stockholders Equity | $9,540,000 | $22,694,000 | $42,460,000 | $84,936,000 |
| Retained Earnings | $-294,331,000 | $-279,216,000 | $-255,527,000 | $-208,140,000 |
Other
| Metric | 2024-12-31 | 2023-12-31 | 2022-12-31 | 2021-12-31 |
|---|---|---|---|---|
| Ordinary Shares Number | $17,640,328 | $17,045,954 | $16,549,984 | $16,164,994 |
| Share Issued | $17,640,328 | $17,045,954 | $16,549,984 | $16,164,994 |
| Tangible Book Value | $9,540,000 | $22,694,000 | $42,460,000 | $79,430,000 |
| Invested Capital | $29,785,000 | $42,189,000 | $71,428,000 | $112,414,000 |
| Working Capital | $22,949,000 | $35,939,000 | $62,988,000 | $103,416,000 |
| Capital Lease Obligations | $2,760,000 | $3,736,000 | $6,233,000 | $587,000 |
| Total Capitalization | $29,362,000 | $41,925,000 | $71,238,000 | $112,414,000 |
| Additional Paid In Capital | $303,853,000 | $301,893,000 | $297,970,000 | $293,060,000 |
| Capital Stock | $18,000 | $17,000 | $17,000 | $16,000 |
| Common Stock | $18,000 | $17,000 | $17,000 | $16,000 |
| Preferred Stock | $0 | $0 | $0 | $0 |
| Long Term Capital Lease Obligation | $1,664,000 | $2,760,000 | $4,493,000 | $0 |
| Current Capital Lease Obligation | $1,096,000 | $976,000 | $1,740,000 | $587,000 |
| Current Accrued Expenses | $7,850,000 | $7,531,000 | $4,202,000 | $6,239,000 |
| Net PPE | $7,684,000 | $8,487,000 | $13,082,000 | $4,772,000 |
| Accumulated Depreciation | $-6,012,000 | $-5,769,000 | $-5,124,000 | $-3,884,000 |
| Gross PPE | $13,696,000 | $14,256,000 | $18,206,000 | $8,656,000 |
| Leases | $3,286,000 | $3,316,000 | $5,223,000 | $1,151,000 |
| Construction In Progress | $1,543,000 | $59,000 | $1,382,000 | $1,855,000 |
| Other Properties | $6,649,000 | $8,598,000 | $10,021,000 | $4,361,000 |
| Machinery Furniture Equipment | $2,218,000 | $2,283,000 | $1,580,000 | $1,289,000 |
| Properties | $0 | $0 | $0 | $0 |
| Treasury Shares Number | - | $0 | - | - |
| Goodwill | - | - | $0 | $5,506,000 |
| Buildings And Improvements | - | - | $4,885,000 | $0 |
Cash Flow Statement (Annual)
Free Cash Flow
| Metric | 2024-12-31 | 2023-12-31 | 2022-12-31 | 2021-12-31 |
|---|---|---|---|---|
| Free Cash Flow | $-13,794,000 | $-15,290,000 | $-36,462,000 | $-22,639,000 |
Operating Activities
| Metric | 2024-12-31 | 2023-12-31 | 2022-12-31 | 2021-12-31 |
|---|---|---|---|---|
| Operating Cash Flow | $-13,279,000 | $-14,462,000 | $-32,144,000 | $-20,269,000 |
| Cash Flow From Continuing Operating Activities | $-13,279,000 | $-14,462,000 | $-32,144,000 | $-20,269,000 |
| Operating Gains Losses | $111,000 | $189,000 | - | - |
Investing Activities
| Metric | 2024-12-31 | 2023-12-31 | 2022-12-31 | 2021-12-31 |
|---|---|---|---|---|
| Capital Expenditure | $-515,000 | $-828,000 | $-4,318,000 | $-2,370,000 |
| Investing Cash Flow | $-515,000 | $-804,000 | $-4,318,000 | $-2,420,000 |
| Cash Flow From Continuing Investing Activities | $-515,000 | $-804,000 | $-4,318,000 | $-2,420,000 |
| Net Other Investing Changes | - | - | - | $-50,000 |
Financing Activities
| Metric | 2024-12-31 | 2023-12-31 | 2022-12-31 | 2021-12-31 |
|---|---|---|---|---|
| Financing Cash Flow | $-663,000 | $-10,632,000 | $-489,000 | $64,683,000 |
| Cash Flow From Continuing Financing Activities | $-663,000 | $-10,632,000 | $-489,000 | $64,683,000 |
| Issuance Of Capital Stock | - | - | $0 | $69,144,000 |
| Net Other Financing Charges | - | - | $-239,000 | $-4,447,000 |
| Net Common Stock Issuance | - | - | $0 | $69,144,000 |
| Common Stock Issuance | - | - | $0 | $69,144,000 |
Other
| Metric | 2024-12-31 | 2023-12-31 | 2022-12-31 | 2021-12-31 |
|---|---|---|---|---|
| Repayment Of Debt | $-861,000 | $-10,938,000 | $-696,000 | $-525,000 |
| Interest Paid Supplemental Data | $1,719,000 | $1,737,000 | $1,732,000 | $1,815,000 |
| End Cash Position | $22,236,000 | $36,693,000 | $62,591,000 | $99,542,000 |
| Beginning Cash Position | $36,693,000 | $62,591,000 | $99,542,000 | $57,548,000 |
| Changes In Cash | $-14,457,000 | $-25,898,000 | $-36,951,000 | $41,994,000 |
| Proceeds From Stock Option Exercised | $198,000 | $306,000 | $446,000 | $511,000 |
| Net Issuance Payments Of Debt | $-861,000 | $-10,938,000 | $-696,000 | $-525,000 |
| Net Long Term Debt Issuance | $-861,000 | $-10,938,000 | $-696,000 | $-525,000 |
| Long Term Debt Payments | $-861,000 | $-10,938,000 | $-696,000 | $-525,000 |
| Net PPE Purchase And Sale | $-515,000 | $-804,000 | $-4,318,000 | $-2,370,000 |
| Sale Of PPE | $0 | $24,000 | $0 | - |
| Purchase Of PPE | $-515,000 | $-828,000 | $-4,318,000 | $-2,370,000 |
| Change In Working Capital | $-3,076,000 | $325,000 | $1,670,000 | $-61,000 |
| Change In Other Current Liabilities | $-976,000 | $-1,010,000 | $-854,000 | $0 |
| Change In Other Current Assets | $63,000 | $-101,000 | $-47,000 | $-167,000 |
| Change In Payables And Accrued Expense | $908,000 | $2,564,000 | $-501,000 | $329,000 |
| Change In Accrued Expense | $600,000 | $2,497,000 | $-1,402,000 | $984,000 |
| Change In Payable | $308,000 | $67,000 | $901,000 | $-655,000 |
| Change In Account Payable | $308,000 | $67,000 | $901,000 | $-655,000 |
| Change In Prepaid Assets | $-1,787,000 | $-654,000 | $-505,000 | $521,000 |
| Change In Receivables | $-1,284,000 | $-474,000 | $3,577,000 | $-744,000 |
| Changes In Account Receivables | $-1,284,000 | $-474,000 | $3,577,000 | $-744,000 |
| Other Non Cash Items | $1,314,000 | $2,928,000 | $1,715,000 | $819,000 |
| Stock Based Compensation | $1,763,000 | $3,617,000 | $4,704,000 | $4,728,000 |
| Depreciation Amortization Depletion | $1,724,000 | $2,168,000 | $1,557,000 | $948,000 |
| Depreciation And Amortization | $1,724,000 | $2,168,000 | $1,557,000 | $948,000 |
| Net Income From Continuing Operations | $-15,115,000 | $-23,689,000 | $-47,387,000 | $-26,851,000 |
| Asset Impairment Charge | - | $0 | $5,903,000 | $0 |
| Deferred Tax | - | $0 | $-306,000 | $148,000 |
| Deferred Income Tax | - | $0 | $-306,000 | $148,000 |
| Issuance Of Debt | - | - | - | $0 |
| Long Term Debt Issuance | - | - | - | $0 |